Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its bevacizumab biosimilar. The approved indications for the biosimilar include the treatment of metastatic colorectal cancer (CRC), recurrent glioblastoma, and advanced metastatic or recurrent non-small cell lung cancer (NSCLC). This approval expands the treatment options available for patients suffering from these serious conditions.
Background on Bevacizumab
The originator bevacizumab, developed by Swiss pharmaceutical giant Roche, was first approved for marketing in the United States in February 2004 and entered the Chinese market in February 2010. It is currently used to treat a range of cancers, including colorectal cancer, non-small cell lung cancer, glioblastoma, hepatocellular carcinoma, ovarian cancer, and cervical cancer. The introduction of Sino Biopharmaceutical’s biosimilar offers an additional therapeutic choice for patients and healthcare providers in China.
Market Landscape
In addition to Sino Biopharmaceutical, several other companies have biosimilar versions of bevacizumab on the local market. These include Roche, Qilu Pharma, Innovent Bio, Boan Bio, Hengrui Medicine, Bio-Thera Solutions, Betta Pharma, Tot Bio, and Henlius Bio. The entry of Sino’s biosimilar into the market further intensifies competition in the bevacizumab space, potentially leading to increased accessibility and affordability of this important cancer treatment.
Future Prospects
The marketing approval from the NMPA is a significant milestone for Sino Biopharmaceutical, as it positions the company to capture a share of the growing biosimilars market in China. With multiple indications approved, the company is well-equipped to address the needs of patients with various types of cancer, contributing to the overall treatment landscape in the country.-Fineline Info & Tech
